McCabe Kenny, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,855 of the $4,897 with a category attached, or 78.7%. 33 manufacturers reported payments, led by Boston Scientific at 38.8% of the total. Reporting peaked in 2019 at $1,907 and has fallen 79.8% since, to $385 in 2025.
Across 89 payments — averaging $55.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Dornier Medtech America, Inc$427
- Neotract Inc.$386
- Teleflex LLC$261
- Procept Biorobotics Corporation$257
- Caldera Medical, Inc$223
- plus $1K from 27 others
What the payments were for
- Travel & lodging$1,01321%
- Food & beverage$3,85579%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 13 | $1,902 |
| Dornier Medtech America, Inc | 4 | $427 |
| Neotract Inc. | 7 | $386 |
| Teleflex LLC | 3 | $261 |
| Procept Biorobotics Corporation | 2 | $257 |
| Caldera Medical, Inc | 1 | $223 |
| Johnson & Johnson | 6 | $147 |
| Myriad Genetic Laboratories, Inc. | 4 | $138 |
| Sumitomo Pharma America, Inc. | 2 | $136 |
| AbbVie | 5 | $103 |
| Urogen Pharma, Inc. | 3 | $75 |
| Olympus America Inc. | 3 | $74 |
| Axonics, Inc. | 3 | $63 |
| Verity Pharmaceuticals Inc. | 3 | $60 |
| Ferring Pharmaceuticals Inc. | 2 | $54 |
| Accord Healthcare, Inc. | 2 | $54 |
| Coloplast | 3 | $53 |
| Merck | 3 | $52 |
| 180 Medical, Inc. | 2 | $52 |
| KARL Storz Endoscopy-america | 1 | $50 |
| Vertex | 2 | $43 |
| Astellas Pharma US Inc | 2 | $40 |
| Novartis | 1 | $35 |
| Amgen | 2 | $34 |
| Endo Pharmaceuticals Inc. | 2 | $30 |
| Medtronic | 1 | $26 |
| Calyxo, Inc. | 1 | $25 |
| Laborie Medical Technologies Corp. | 1 | $20 |
| Bayer | 1 | $19 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $16 |
| Dendreon Pharmaceuticals LLC | 1 | $16 |
| Progenics Pharmaceuticals, Inc. | 1 | $14 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GREENLIGHT$987
- AquaBeam Robotic System$257
- AMS$236
- Desara$223
- Dornier MedTech$195
- UroLift System$141
- Lithotripters & Accessories$119
- REZUM$117
- ORGOVYX$116
- UroLift$102
How this compares
$4,897 in reported general payments places this provider in the 75th percentile of 114 urology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 11 | $146,587 |
| MyrbetriqMirabegron | 82 | $56,164 |
| OrgovyxRelugolix | 16 | $42,050 |
| Oxybutynin Chloride ErOxybutynin Chloride | 298 | $3,568 |
| Tamsulosin Hcl | 306 | $2,447 |
| Estradiol | 26 | $1,896 |
| Finasteride | 201 | $1,834 |
| Trospium Chloride ErTrospium Chloride | 12 | $1,336 |
| Methenamine Hippurate | 24 | $1,105 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 24 | $615 |
| Solifenacin Succinate | 18 | $439 |
| Potassium Chloride | 14 | $315 |
| Desmopressin Acetate | 13 | $290 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $212 |
| Ciprofloxacin Hcl | 38 | $136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $40 | $202,75093 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $136 | $42,05016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 114 urology providers in Iowa.
Other urology in Clive
- Ryan DornbierClive$55K
- Mark KellermanClive$14K
- Trevor WildClive$10K
- Stephanie Courson PothovenClive$8K
- Brian GallagherClive$4K
- Jacob JippClive$3K
- Vignesh PackiamIowa City$112K
- Annah VollstedtIowa City$66K
- Bradley EricksonIowa City$65K
- Michael OdonnellIowa City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.